Viatris has completed all previously announced
divestitures, with the closure of its Over-the-Counter business marking this milestone. Regarding earnings, Viatris' Q1 results lagged behind estimates, adversely affecting the stock's performance. Despite this, expert projections surmise a beat might be in store for future earnings' reports. While the
U.S. Department of Justice has informed Viatris that it no longer sees Mylan, a Viatris entity, as a subject for its generic drug industry scrutiny, sales of major products like Lipitor and Norvasc have slackened, impacting Viatris' earnings and prompting a lowering of the annual forecast. A significant development is the launch of the first bioequivalent generic version of Copaxone® 20 mg/mL in Canada. Unveiling Viatris's value, some experts believe the company's stock is
undervalued, even with its billion-dollar
buyback potential. Insider trading has shown that the Chief Legal Officer and the President of Greater China have sold substantial shares of Viatris. Despite potential growth hurdles, the company has met its 2023 financial targets and envisions continuous growth for 2024.
Viatris VTRS News Analytics from Mon, 07 Aug 2023 07:00:00 GMT to Fri, 05 Jul 2024 15:58:00 GMT -
Rating -3
- Innovation 0
- Information 5
- Rumor -2
